Amendments to Optometry Act allow Canadian optometrists to prescribe medication

Article

The Optometry Amendment Act will allow optometrists to prescribe and administer drugs to persons with certain eye conditions.

 

Winnipeg, Manitoba-The Optometry Amendment Act, scheduled to take effect July 15, will allow optometrists to prescribe and administer drugs to persons with certain eye conditions, said Theresa Oswald, Health Minister of Manitoba.

“Until now, optometrists treating patients requiring medication had to refer them to ophthalmologists or other physicians,” Oswald said. “The amendments will improve access to eye care and reduce wait times for treatment for patients.”

Under the new legislation, qualified optometrists will be able to prescribe and administer certain drugs to treat eye infections, glaucoma, uveitis, dry eye, and ocular allergies. Additionally, qualified optometrists will be able to collaborate with ophthalmologists to treat more serious eye diseases.

The amendments will also expand the scope of practice of optometrists so they may remove superficial foreign bodies from the eye, and order and receive screening and diagnostic tests. The change has the support of the Manitoba Association of Optometrists  (MAO).

“This is great news for our patients and everyone in Manitoba,” said Neil Campbell, OD, MAO president. “Most of our members have been educated and trained to prescribe medications for years. We are pleased that the Manitoba government has made changes that will broaden access to medically necessary services across the province.”

Optometrists provide approximately 80% of all first contact, primary vision, and eye health examinations in Manitoba, according to the MAO.

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.